NGeneBio is excited to announce its participation in the Korean Society of Diagnostic Genetics Symposium, scheduled for December 7, 2022. The symposium will delve into various topics related to trends in circulating tumor nucleic acid (ctDNA) analysis technology, relevant issues, and the ethical, legal, and social implications (ELSI) of utilizing genomic data, which are actively applied in clinical practice.

During this event, NGeneBio will unveil plans for the commercialization and technological collaboration for 'Minimal Residual Disease (MRD) Testing,' expanding its NGS precision diagnostic testing platform to encompass processes from diagnosis to monitoring for leukemia patients following diagnosis and treatment. NGeneBio aims to launch products that will facilitate this process within the year.

We appreciate your interest in NGeneBio's endeavors!